ClinicalTrials.Veeva

Menu

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat (NEON-NPDR)

Bayer logo

Bayer

Status and phase

Completed
Phase 2

Conditions

Diabetic Retinopathy

Treatments

Drug: Runcaciguat (BAY1101042)
Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04722991
20739
2020-002333-15 (EudraCT Number)

Details and patient eligibility

About

This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48 weeks of treatment. In addition, vision threatening complications will be recorded throughout the study and assessed as secondary efficacy endpoint.

Enrollment

109 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

  • Moderately severe to severe NPDR in the study eye: Diabetic Retinopathy Severity Scale (DRSS) levels 47 or 53
  • Diabetes type 1 or 2
  • Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

Main Exclusion Criteria:

  • Presence or history of macular edema involving the center of the macula
  • Any kind of neovascular growth in the study eye, including anterior segment neovascularization
  • Arterial hypotension with systolic blood pressure < 100 or diastolic blood pressure < 60mmHg
  • Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 3 x Upper limit of normal (ULN) or bilirubin ≥ 1.5 ULN at screening, known ascites
  • Estimated glomerular filtration rate (eGFR CKD-EPI) below 30 ml/min/1.73 m^2 at screening
  • Any prior systemic anti-Vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye
  • Any prior intraocular steroid injection in the study eye
  • Any prior grid or focal laser photocoagulation within 500 microns of the foveal center or any prior Pan-retinal photocoagulation (PRP) in the study eye
  • Use of nitrates or Nitric oxide (NO) donors (such as amyl nitrate) in any form including topical; Phosphodiesterase 5 (PDE5) inhibitors, nonspecific PDE inhibitors within 1 week or less than 5 half-lives (whichever is longer) before first study drug administration

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

109 participants in 2 patient groups, including a placebo group

Runcaciguat (BAY1101042)
Experimental group
Treatment:
Drug: Runcaciguat (BAY1101042)
Placebo
Placebo Comparator group
Treatment:
Other: Placebo

Trial documents
2

Trial contacts and locations

58

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems